Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12615001221549
Ethics application status
Approved
Date submitted
5/11/2015
Date registered
9/11/2015
Date last updated
3/09/2019
Date data sharing statement initially provided
3/09/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Management of Chronic Diabetic Foot Ulcer by Extracorporeal Shockwave Therapy at The Townsville Hospital
Query!
Scientific title
Efficacy of Extracorporeal Shockwave Therapy for Management of Diabetic Foot Ulcer at The Townsville Hospital
Query!
Secondary ID [1]
287795
0
Nil Known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes
296676
0
Query!
Diabetic Foot Ulcer
296677
0
Query!
Condition category
Condition code
Metabolic and Endocrine
296904
296904
0
0
Query!
Diabetes
Query!
Skin
296905
296905
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Twenty five subjects with diabetic foot ulcer will be treated fortnightly with standard 20-minute wound care (debridement and normal saline dressing) first, to be followed by 10 minutes of shockwave therapy for a period of 6 weeks. A handheld shockwave device will be applied gently against the ulcer surface by treating podiatrist to deliver 300 + 100/cm2 impulses of shockwave at 0.11 mJ/cm2 energy flux density during which the participant may feel light vibration and then crossover for another 6 weeks on fortnightly standard wound care alone with total duration of the study period of 12 weeks. Log of device use time will be utilized to monitor adherence of the shockwave therapy.
Query!
Intervention code [1]
293193
0
Treatment: Other
Query!
Intervention code [2]
293194
0
Treatment: Devices
Query!
Comparator / control treatment
Twenty five subjects with diabetic foot ulcer will be treated with 20-minute standard wound care (debridement and normal saline dressing) fortnightly for a period of 6 weeks and then crossover for another 6 weeks on fortnightly 300 + 100/cm2 impulses of shockwave at 0.11 mJ/cm2 energy flux density to be applied evenly to the ulcer surface in addition to standard wound care alone giving a total duration of the study period of 12 weeks.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
296518
0
Partial or complete foot ulcer healing to be assessed fortnightly using specialized 3-D camera
Query!
Assessment method [1]
296518
0
Query!
Timepoint [1]
296518
0
Fortnightly assessment at the time of treatment for the 12-week study period
Query!
Secondary outcome [1]
318656
0
Proportion of participants who achieve a significant (20%) reduction of serum levels if interleukin 6 (IL-6)
Query!
Assessment method [1]
318656
0
Query!
Timepoint [1]
318656
0
Completion of the 12-week study
Query!
Eligibility
Key inclusion criteria
1. Diabetes age >18 years
2. Stable documented diabetic foot ulcer of full-thickness skin defect requiring >14 days of healing.
3. Exclusion of other etiologies of foot ulcer.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Current index foot ulcer of any non-diabetic pathophysiology (e.g. rheumatoid, radiation-related, vasculitis-related, calciphylaxis, or dystrophic calcinosis cutis, etc.).
2. Any major surgery up to 4 weeks prior to the day of enrolment or any planned surgery prior to study completion including any major surgical intervention for the diabetic foot ulcer.
3. Significant medical conditions that potentially impair wound healing and/or alter the concentration of serum immune markers including hepatic, respiratory or cardiac failure, aplastic anemia, autoimmune diseases (e.g. Lupus erythematodes, scleroderma, etc.), chronic inflammatory diseases (e.g. inflammatory bowel disease, inflammatory or rheumatoid arthritis, etc.) and any active malignancies including cancerous or pre-cancerous lesions in the ulcer area other than basal cell carcinoma.
4. Treatment with normothermic or hyperbaric oxygen therapy.
5. Skin and dermal substitutes within 30 days prior to study enrolment.
6. Enzymatic debridement treatment.
7. Participation in any other clinical trial.
8. Inability to comply with study protocol.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All subjects who fit the selection criteria will be invited to participate, and if willing will be provided with information on the study and participant consent will be obtained and then randomized. Patients in each stratum will be assigned numbers using a central stratified randomization scheme.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The randomization list will be prepared by an independent statistician by the method of computer-generated random numbers for each treatment. Patients in each stratum will be assigned numbers using a central stratified randomization scheme designed to provide 1:1 of patients in the 2 groups. Patients will be randomized to initial standard care + shockwave to be followed by standard care alone for another 6 weeks. The other group will have first 6 weeks of standard care alone to be followed by 6 weeks of both shockwave therapy and standard care.
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The appropriate sample size was attained by assuming an anticipated difference in wound healing time of 12% (=66 days from an assumed mean of 75 days for diabetic foot ulcer patients at week 12 between the intervention and control group and a within patient variability (standard deviation) of 10days. A power set to 80% yields a calculated sample size of 22 patients per arm. Adding an additional estimated attrition rate of close to 15% = 3 patients per arm leads to an overall planned sample size of 25 patients per arm, and 50 patients in total.
Descriptive statistics including frequency tables and graphs will be provided for all variables, as well as for the changes from baseline within each treatment and the differences between the treatment groups at each visit. All data will be analysed using SPSS Version 22. Tests for normality will be performed and based on the outcome, parametric or nonparametric tests will be employed to determine the differences between the groups. The results will be given as mean + standard deviation. Chi-squared analysis will be performed for categorical variables and student T test or Mann Whitney U test will be carried out for continuous variables for parametric or non-parametric data respectively. ANOVA will be used for determining differences among multiple groups. A p value <0.05 will be considered significant.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
1/01/2016
Query!
Actual
2/01/2017
Query!
Date of last participant enrolment
Anticipated
4/10/2019
Query!
Actual
Query!
Date of last data collection
Anticipated
10/01/2020
Query!
Actual
Query!
Sample size
Target
50
Query!
Accrual to date
46
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
4564
0
The Townsville Hospital - Douglas
Query!
Recruitment postcode(s) [1]
12180
0
4814 - Douglas
Query!
Funding & Sponsors
Funding source category [1]
292327
0
Government body
Query!
Name [1]
292327
0
Queensland Government Department of Health
Query!
Address [1]
292327
0
Queensland Policy and Advisory Committee for new Technology
Leve 2, 15 Butterfield St
Herston QLD 4006
Query!
Country [1]
292327
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
The Townsville Hospital
Query!
Address
100 Angus Smith Drive
Douglas
QLD 4814
Query!
Country
Australia
Query!
Secondary sponsor category [1]
291002
0
None
Query!
Name [1]
291002
0
Query!
Address [1]
291002
0
Query!
Country [1]
291002
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
293794
0
Townsville Hospital and Health Service Human Resaerch Ethics Committee
Query!
Ethics committee address [1]
293794
0
100 Angus Smith Drive
Douglas
QLD 4814
Query!
Ethics committee country [1]
293794
0
Australia
Query!
Date submitted for ethics approval [1]
293794
0
28/04/2015
Query!
Approval date [1]
293794
0
30/07/2015
Query!
Ethics approval number [1]
293794
0
-
Query!
Summary
Brief summary
Extracorporeal shockwave therapy (ESWT) is a new technology in the care of chronic non-healing wounds. The technology delivers high-energy pressure waves into the wound thereby enriching the ulcer with adequate blood through formation of new blood vessels. It also inhibits infection with its antibacterial property. Furthermore, it stimulates the body to produce natural growth factors which helps in repairing the damaged tissues of the wound. Recently, ESWT was reported to be effective in the initiation and acceleration of wound healing in various clinical settings including longstanding diabetic foot ulcers. The effectiveness of ESWT in wound healing, especially in treatment of diabetic foot ulcers has been demonstrated in numerous trials (1-2). It has been shown to be more effective value for money compared to hyperbaric oxygen therapy in management of chronic diabetic wounds (3). There are evidences demonstrating reduced length of stay for admitted patients when using this treatment model (3-4). Its safety profile has been proven in various studies (1-4). Numerous scientific investigations have been conducted on biological mechanism of action of ESWT in animals and humans and both proved to be safe and effective (5-6). Furthermore, it has been demonstrated that ESWT therapy achieves long-term healing results in diabetic wound care (7). Thus using this technology at The Townsville Hospital would likely improve the weighted activity unit per bed day figure for medical patients by increasing the total bed days saved, as that capacity will be filled by current access block / unmet demand of the chronic diabetic foot wounds at the hospital.
In spite of these facts, ESWT technology has not been utilised in the care of diabetic foot ulcer patients in Australia in general and at The Townsville Hospital in particular. This is despite the fact that this technology is non-invasive, simple to use, well tolerated by patients, and only needs to be administered on fortnightly basis whereas even more invasive therapies need more frequent administration. Furthermore, ESWT is applied through an unfocused applicator which assures an almost painless treatment with no anaesthesia required and each therapy session only taking about 10 to 30 minutes.
The main objective of this study was to evaluate wound healing rate and anti-inflammatory effect of shockwave therapy in subjects with diabetic foot ulcer at the Townsville Hospital, Australia.
References
1. Wang C, Kuo Y, Wu R et al. J Surg Res. 2009; 152: 96-103.
2. Moretti B, Notarnicola A. et al. BMC Musculoskeletal Disorders 2009, 10:54, 1-8.
3. Wang CJ, Wu RW, Yang YJ. Diabetes Res Clin Pract. 2011 ;92(2):187-93.
4. Saggini R, Figus A, et al.. Ultrasound Med Biol. 2008 Aug;34(8):1261-71.
5. Mittermayr R, Antonic V, et al. Wound Repair Regen. 2012;20(4):456-65.
6. Kuo YR, Wang CT, et al. Wound Repair Regen. 2009;17(4):522-30.
7. Wang CJ et al. J Surg Res. 2014;189(2):366-72.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
39414
0
Prof Usman H. Malabu
Query!
Address
39414
0
The Townsville Hospital
100 Angus Smith Drive
Douglas
QLD 4814
Query!
Country
39414
0
Australia
Query!
Phone
39414
0
+61-7-4433 1111
Query!
Fax
39414
0
+61-7-4433 2239
Query!
Email
39414
0
[email protected]
Query!
Contact person for public queries
Name
39415
0
Prof Usman H. Malabu
Query!
Address
39415
0
The Townsville Hospital
100 Angus Smith Drive
Douglas
QLD 4814.
Query!
Country
39415
0
Australia
Query!
Phone
39415
0
+61-7-4433 1111
Query!
Fax
39415
0
+61-7-4433 2239
Query!
Email
39415
0
[email protected]
Query!
Contact person for scientific queries
Name
39416
0
Prof Usman H. Malabu
Query!
Address
39416
0
The Townsville Hospital
100 Angus Smith Drive
Douglas
QLD 4814.
Query!
Country
39416
0
Australia
Query!
Phone
39416
0
+61-7-4433 1111
Query!
Fax
39416
0
+61-7-4433 2239
Query!
Email
39416
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Deidentified, individual participant data underlying published results only
Query!
When will data be available (start and end dates)?
Beginning 3 months and ending 5 years following main results publication
Query!
Available to whom?
researchers who provide a methodologically sound proposal
Query!
Available for what types of analyses?
for IPD meta-analyses, etc.
Query!
How or where can data be obtained?
[email protected]
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Doc. No.
Type
Citation
Link
Email
Other Details
Attachment
4315
Study protocol
[email protected]
4316
Statistical analysis plan
[email protected]
4317
Ethical approval
[email protected]
4318
Informed consent form
[email protected]
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF